VGF: Physiology and What Research Reports

What VGF Is

VGF is a secreted protein precursor — a prohormone — that is packaged into dense-core secretory granules and cleaved by prohormone convertases into a family of smaller peptides. The name is historical: VGF was first catalogued as a nerve growth factor–inducible gene product, so the letters do not describe a function. Individual fragments are usually named after their amino-acid sequences or their discovery series, including the neuroendocrine regulatory peptide (NERP) group and the C-terminal AQEE- and GGEE-peptides that have been measured in cerebrospinal fluid as candidate markers across dementia types (PMID 41186756). Because one precursor yields several peptides with different reported activities, papers about "VGF" may be describing the full precursor, a single fragment, or the gene.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Nothing here describes a protocol, and no VGF-derived peptide is presented as a treatment.

Where VGF Is Produced and How It Is Released

VGF expression is concentrated in cells that use the regulated secretory pathway: neurons, neuroendocrine cells and pancreatic islet cells. In pancreatic beta cells, researchers reported that the prohormone VGF regulates beta-cell function through insulin secretory granule biogenesis, linking the precursor to the machinery that builds the granules rather than to insulin itself (PMID 28877479). A later study using a targeted deletion reported that NERP-4–deleted VGF impaired beta-cell granulogenesis and insulin secretion, indicating that a single internal fragment contributed to the phenotype (PMID 41405840).

On the export side, a cell-biology study reported that secretion of VGF relies on the interplay between LRRK2 — a kinase better known from Parkinson's disease genetics — and post-Golgi v-SNARE proteins, placing VGF release downstream of trafficking components rather than of transcription alone (PMID 36905628).

What the Literature Reports About VGF Functions

Islet biology and insulin granules

Two of the clearest mechanistic findings concern the pancreas. The 2017 report described VGF as a regulator of beta-cell function via secretory granule biogenesis (PMID 28877479), and the 2025 NERP-4 deletion work reported impaired granulogenesis and reduced insulin secretion when that fragment was removed from the precursor (PMID 41405840). Together these papers frame VGF as part of the granule-building apparatus in endocrine cells.

Brain, dopamine systems and neurodegeneration

A 2024 study described an NR4A2/VGF pathway that fuelled inflammation-induced neurodegeneration by promoting neuronal glycolysis, a report in which VGF acted as a downstream effector of an inflammatory transcriptional programme rather than as a purely protective factor (PMID 39145444). In a rat model, researchers reported that early dopaminergic dysfunction induced PRO-VGF changes in both blood and brain following alpha-synuclein overexpression, suggesting the precursor tracked with early disease processes in that model (PMID 41166007). The LRRK2 trafficking study adds a separate genetic link between VGF secretion and Parkinson's-associated biology (PMID 36905628).

Body weight and metabolism

A 2021 Peptides paper evaluated VGF-derived peptides as potential anti-obesity candidates in pre-clinical animal models, which is the main published context in which synthetic VGF fragments have been administered to animals rather than studied only as endogenous molecules (PMID 33245952). Separately, a medicinal-chemistry group synthesised and evaluated N-(4-benzylphenyl)piperazines as VGF inducers, an approach that raised endogenous VGF expression instead of delivering a peptide (PMID 29871846).

How VGF Is Measured and Studied

Because VGF yields multiple products, measurement depends on which epitope an assay recognises. Common approaches in the cited literature include:

• Fragment-specific immunoassays in fluid. AQEE- and GGEE-peptides were measured and reported to differentiate between dementia types (PMID 41186756).
• Precursor measurement in blood and tissue. PRO-VGF changes were reported in blood and brain of rats with alpha-synuclein overexpression (PMID 41166007).
• Genetic deletion models. Removing NERP-4 from the precursor allowed researchers to attribute granule and secretion defects to a defined region (PMID 41405840).
• Trafficking and secretion assays. VGF release was used as a readout for LRRK2 and post-Golgi v-SNARE function (PMID 36905628).
• Expression profiling in tumour tissue. Reduced expression of secretogranin VGF was reported in laryngeal squamous cell carcinoma (PMID 38108073).

VGF in Cancer Research

VGF appears in oncology papers as a secreted factor shaping the tumour microenvironment, with direction of effect depending on tumour type.

Safety and Adverse Events in VGF Research: What Studies Report

The verified literature summarised here is mechanistic, biomarker-based or preclinical, and none of these reports is a human safety trial of an administered VGF peptide. The closest to an intervention study is the pre-clinical animal evaluation of VGF peptides as anti-obesity candidates (PMID 33245952) and the small-molecule VGF-inducer chemistry work (PMID 29871846); neither establishes a human safety profile. Some findings also cut in opposite directions — for example, VGF appeared downstream of an inflammatory pathway driving neurodegeneration in one model (PMID 39145444) while supporting metastatic colonisation in another (PMID 39422674), which is why "more VGF" cannot be read as inherently good or bad.

Why the Term Comes Up

Readers usually meet VGF in three places: neurodegeneration biomarker papers, metabolic and obesity peptide literature, and tumour-microenvironment research. Its fragments are sold as research chemicals in some markets, but the peptides discussed above are laboratory materials studied in cells and animals, not approved medicines, and the cited work does not support claims about human outcomes.

Limitations of the Evidence

1. Findings in rodents and cell systems may not transfer to humans (PMID 41166007).
2. Different fragments of the same precursor were studied, so results about NERP-4 (PMID 41405840) do not automatically apply to AQEE- or GGEE-peptides (PMID 41186756).
3. Biomarker associations describe correlation with disease categories, not causation or treatment benefit.

References

• The Prohormone VGF Regulates β Cell Function via Insulin Secretory Granule Biogenesis (Cell Reports, 2017)
• NERP-4-Deleted VGF Impairs β-Cell Granulogenesis and Insulin Secretion (FASEB Journal, 2025)
• Secretion of VGF relies on the interplay between LRRK2 and post-Golgi v-SNAREs (Cell Reports, 2023)
• VGF AQEE- and GGEE-peptides differentiate between dementia types (Journal of Neurology, 2025)
• Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression (Neurochemical Research, 2025)
• The NR4A2/VGF pathway fuels inflammation-induced neurodegeneration via promoting neuronal glycolysis (Journal of Clinical Investigation, 2024)
• Evaluation of VGF peptides as potential anti-obesity candidates in pre-clinical animal models (Peptides, 2021)
• Synthesis and evaluation of N-(4-benzylphenyl)piperazines as VGF inducers (Bioorganic & Medicinal Chemistry Letters, 2018)
• Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops (Advanced Science, 2024)
• Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer (Cancer Research, 2025)
• Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis (Cell Communication and Signaling, 2024)
• Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma (Oncology Letters, 2024)